Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Association of provider opioid prescribing practices and the Centers for Medicare and Medicaid Services hierarchical condition category score: A retrospective examination of correlation between the volume of provider-prescribed opioid medications and provi
North, Frederick , Tulledge‐Scheitel, Sidna M. , Crane, Sarah J.

Mayo Clinic

SAGE Open Medicine | March 30, 2017 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/2050312117701024 | PMID 28491306 Get It

Objective: Opioids are being prescribed at increasing rates in primary care practices, and among individual providers there is significant variability in opioid prescribing. Primary care practices also vary significantly in complexity of their patients, ranging from healthy patients to those with multiple comorbidities. Our objective was to examine individual primary care providers for an association between their opioid prescribing and the complexity/risk of their panel of patients (a panel of patients is a group of patients whose medical care is the responsibility of a specific healthcare provider or care team). Methods: We retrospectively examined 12 months of opioid prescription data from a primary care practice. We obtained counts of opioids prescribed by providers in the Mayo Clinic, Rochester, Minnesota primary care practice. For patients paneled (assigned) to family medicine and internal medicine, we used the Centers for Medicare and Medicaid Services hierarchical condition category patient risk score as a measure of patient complexity. After adjusting the opioid counts for panel patient count (to get opioid counts per patient), we used linear regression analysis to determine the correlation between the hierarchical condition category risk and the amount of opioid prescribed by individual providers. Results: Among our combined 103 primary care providers, opioid unit counts prescribed per patient were highly correlated with the providers’ hierarchical condition category panel risk score (r 2 = 0.54). After excluding three outliers, r 2 was 0.74. With and without the outliers, the correlation was very significant (p < 0.0001). Subgroup analysis of panels with hierarchical condition category ⩽ 0.45 showed no correlation of opioid prescribing volume with hierarchical condition category (r 2 < 0.02; p = 0.32). Provider panels with hierarchical condition category > 0.45 showed significant correlation with hierarchical condition category (r 2 = 0.26; p = 0.001). Conclusion: When examining differences in primary care providers’ opioid prescribing practices, the Centers for Medicare and Medicaid Services endorsed risk score (the hierarchical condition category score) can help adjust for population differences of a provider’s patients.
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
Escudier, Bernard , Pal, Sumanta K. , Hainsworth, John D. , Choi, YounJeong, Huseni, Mahrukh , Fine, Gregg, Powles, Thomas, McDermott, David F. , Atkins, Michael B. , Motzer, Robert J. , Rini, Brian I. , Fong, Lawrence , Joseph, Richard W. , Stadler, Walter M. , Hutson, Thomas E. , Ravaud, Alain , Bracarda, Sergio , Suárez, Cristina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 431-431

10.1200/jco.2017.35.6_suppl.431 Get It

431 Background: While targeting VEGF improves outcomes for mRCC pts, resistance invariably develops, often within the first year. Here, we describe the efficacy and safety of atezo (anti-PD-L1) with bev (anti-VEGF) and atezo monotherapy vs sun (TKI) in first-line mRCC. Methods: Treatment-naïve mRCC pts were enrolled in a hypothesis generating Ph II study (IMmotion150; NCT01984242) and randomized to atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w, atezo alone or sun 50 mg PO QD 4 wk on/2 wk off. Crossover to atezo + bev after disease progression was allowed for pts receiving atezo or sun. PD-L1 expression was scored on tumor-infiltrating immune cells (IC, SP142 IHC assay). Coprimary endpoints were PFS (RECIST v1.1 by independent review [IRF]) in ITT pts and pts with PD-L1 expression on ≥ 1% of IC (PD-L1+). Results: Baseline characteristics were comparable across arms and between ITT and PD-L1+ pts. The majority of sun and atezo pts subsequently received atezo + bev. Median survival follow up was 20.7 mo. The PFS HR in ITT pts for atezo + bev vs sun was 1.00 and 1.19 for atezo vs sun. In PD-L1+ pts, the PFS HR for atezo + bev vs sun was 0.64 and 1.03 for atezo vs sun (table). Tx-related Gr 3-4 AEs were seen in 40%, 16% and 57% of pts in the atezo + bev, atezo and sun arms, respectively. AEs leading to death occurred in 3%, 2% and 2% of pts, respectively. Conclusion: Atezo + bev resulted in encouraging antitumor activity in the PD-L1+ subgroup of first-line RCC pts. Atezo + bev safety is consistent with the known profile of atezo and bev individually. The clinical benefit of atezo + bev vs sun will be evaluated in the ongoing Ph III study IMmotion151 (NCT02420821). Clinical trial information: NCT01984242. [Table: see text]
Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.
Hurwitz, Herbert I. , Hainsworth, John D. , Bose, Ron , Burris, Howard A. , Guo, Shuangli, Yoo, Bongin, Beattie, Mary, Tayama, Darren, Bryce, Alan H. , Kurzrock, Razelle , Meric‐Bernstam, Funda , Spigel, David R. , Swanton, Charles , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 348-348

10.1200/jco.2017.35.6_suppl.348 Get It

348 Background: Patients (pts) with mUC have few treatment options beyond the second-line setting. HER2 gene amplification has been reported in a minority of pts with UC, but there have been anecdotal reports of the activity of HER2-targeted agents. MyPathway is a multi-basket study evaluating the efficacy and safety of targeted therapies in non-indicated tumor types harboring relevant molecular alterations. We present preliminary data for pts with HER2-positive mUC receiving HER2-targeted treatment with pertuzumab + trastuzumab. Methods: MyPathway (NCT02091141) is an open-label, multicenter, phase IIA study. Pts in this subset analysis had refractory mUC with HER2 amplification or putative activating mutations by gene sequencing, FISH, or IHC. Pts received standard doses of pertuzumab + trastuzumab without chemotherapy until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed overall response rate (RECIST v1.1). Results: As of July 31, 2016, 12 pts with platinum-resistant HER2-positive mUC (HER2-amplified, n=9; HER2-mutated, n=3) have been enrolled. At a median follow-up of 5.4 (range 0.9–14.5) mos, 1 pt had complete response (CR, ongoing at 12.5 mos), 2 had partial responses (PR; duration of response, 3.7 and 5.5 mos), and 2 had stable disease (SD) for >4 mos (Table). Safety was consistent with the product labels. Conclusions: Preliminary results indicate that the combination of pertuzumab + trastuzumab has activity in previously treated HER2-amplified mUC, including a durable CR in a pt with peritoneal metastases. Accrual to MyPathway is ongoing. Clinical trial information: NCT02091141. [Table: see text]
A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
Krishnamurthy, Anuradha , Stein, Mark N. , Sanoff, Hanna K. , Lee, James J. , Hansen, Aaron R. , Malhotra, Usha , Rippke, Sarah, Davis, S. Lindsey , Messersmith, Wells A. , Eckhardt, S. Gail, Dasari, Arvind , Lockhart, A. Craig , Bekaii‐Saab, Tanios , Yao, James C. , Meric‐Bernstam, Funda , Lieu, Christopher H. , Sanoff, Hanna , Hansen, Aaron R

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 609-609

10.1200/jco.2017.35.4_suppl.609 Get It

609 Background: Targeting MEK is of interest in the development of novel agents for treatment of many malignancies. However, better strategies are needed to overcome acquired resistance to MEK inhibitors. Preclinical studies have shown Wnt pathway overexpression in KRAS mutant cell lines resistant to the MEK inhibitor, Selumetinib. The combination of selumetinib and cyclosporin A (CsA), a non-canonical WnT pathway modulator, demonstrated antitumor activity in patient-derived xenograft (PDX) models. We are conducting an NCI CTEP-approved Phase I/IB trial (NCI # 9571/COMIRB # 13-2628) of selumetinib and CsA combination. Biomarkers of response to therapy are being co-developed. We hypothesize that this combination will be safe and potentially effective in patients with mCRC and that upregulation of FZD2 may predict for sensitivity. Methods: Phase I trial with initial dose escalation investigating the combination of selumetinib and CsA in patients with advanced solid tumors (n = 18) followed by an expansion cohort in patients with irinotecan and oxaliplatin-refractory mCRC (n = 20). The expansion cohort utilizes a selumetinib “run-in” to evaluate efficacy in RAS-WT and RAS-MT mCRC to identify those patients most likely to respond to the combination. Results: 18 patients were enrolled in the dose escalation phase and 10 patients have been enrolled in the dose expansion phase as of September 2016. Grade 1 or 2 nausea and rash were reported as the most common AEs. Most commonly reported Grade 3 or 4 toxicities were hypertension, elevated liver enzymes and rash. Three DLTs were reported with Grade 3 hypertension noted at dose level 1 and 2 and grade 3 rash reported at dose level 2. The maximum tolerated dose was defined as Selumetinib 75 mg BID and CsA 2 mg/kg BID on a 28-day cycle. Two partial responses and sixteen stable disease responses have been observed. Six patients have exhibited progressive disease. Conclusions: Selumetinib in combination with cyclosporin A appears to be well-tolerated with evidence of activity in solid tumors. Expansion cohort will complete enrollment this month. Clinical trial information: NCT02188264.
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
Bendell, Johanna C. , O’Neil, Bert H. , Starodub, Alexander, Jonker, Derek J. , Hálfdánarson, Þorvarður R. , Edenfield, William J. , El‐Rayes, Bassel F. , Pitot, Henry C., Hobday, Timothy J. , Gao, Yuan , Grothey, Axel, Borodyansky, Laura, Li, Chiang, Hubbard, Joleen M. , Li, Youzhi , El-Rayes, Bassel F , Halfdanarson, Thorvardur R

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 593-593

10.1200/jco.2017.35.4_suppl.593 Get It

593 Background: Cancer stem cells or stemness-high cancer cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses cancer stemness by targeting Stat3-driven gene transcription. Preclinical studies suggest that napabucasin sensitizes heterogeneous cancer cells to chemotherapeutics and targeted agents. Methods: This study was performed to assess signs of anti-tumor activity of napabucasin in combination with FOLFIRI +/- Bev in CRC pts. Napabucasin was administered at 240 mg BID. FOLFIRI (5-FU 400 mg/m2 bolus with 2400 mg/m2, irinotecan 180 mg/m2, and leucovorin 400 mg/m2 infusion) +/- Bev 5 mg/kg was administered biweekly until disease progression or other discontinuation criterion. pSTAT3 status of archival tumor tissue was assayed by immunohistochemistry using the H-score with pSTAT3highdefined as ≥ 5% pSTAT3+ cancer cells and tumor stroma staining at ≥ 2+ intensity. Results: 63 CRC pts with an average of >2 prior therapy lines were enrolled. No pharmacokinetic interactions or dose-limiting toxicity was observed. Most common adverse events (AEs) included grade 1/2 diarrhea, nausea, vomiting and fatigue. 25 pts had grade 3 AEs, including diarrhea (14), fatigue (4), dehydration (2), electrolyte imbalance (4), nausea (1) and weight loss (1) resolved with dose reduction and supportive care. Among 63 pts enrolled who received RECIST evaluation, disease control (CR+PR+SD) was observed in 49 pts (86%) with an overall response (CR+PR) of 28% with 1 pt achieving CR. Clinical trial information: NCT02024607. Conclusions: This phase Ib/II study suggests napabucasin may sensitize chemorefractory CRC to FOLFIRI +/- Bev. Encouraging signs of synergistic activity between napabucasin and FOLFIRI was observed in CRC pts regardless of pSTAT3 status.[Table: see text]
KCNQ1 p.L353L affects splicing and modifies the phenotype in a founder population with long QT syndrome type 1
Kapplinger, Jamie D., Erickson, Anders C. , Asuri, Sirisha, Tester, David J. , McIntosh, Sarah, Kerr, Charles R., Morrison, Julie, Tang, Anthony, Sanatani, Shubhayan , Arbour, Laura , Ackerman, Michael J. , Tang, Anthony , Sanatani, Shubhayan

Mayo Clinic

Journal of Medical Genetics | March 6, 2017 | Volume: 54 | Issue: 6 | Pages: 390-398

10.1136/jmedgenet-2016-104153 | PMID 28264985 Get It

Background Variable expressivity and incomplete penetrance between individuals with identical long QT syndrome (LQTS) causative mutations largely remain unexplained. Founder populations provide a unique opportunity to explore modifying genetic effects. We examined the role of a novel synonymous KCNQ1 p.L353L variant on the splicing of exon 8 and on heart rate corrected QT interval (QTc) in a population known to have a pathogenic LQTS type 1 (LQTS1) causative mutation, p.V205M, in KCNQ1-encoded Kv7.1. Methods 419 adults were genotyped for p.V205M, p.L353L and a previously described QTc modifier (KCNH2-p.K897T). Adjusted linear regression determined the effect of each variant on QTc, alone and in combination. In addition, peripheral blood RNA was extracted from three controls and three p.L353L-positive individuals. The mutant transcript levels were assessed via qPCR and normalised to overall KCNQ1 transcript levels to assess the effect on splicing. Results For women and men, respectively, p.L353L alone conferred a 10.0 (p=0.064) ms and 14.0 (p=0.014) ms increase in QTc and in men only a significant interaction effect in combination with the p.V205M (34.6 ms, p=0.003) resulting in a QTc of ∼500 ms. The mechanism of p.L353L's effect was attributed to approximately threefold increase in exon 8 exclusion resulting in ∼25% mutant transcripts of the total KCNQ1 transcript levels. Conclusions Our results provide the first evidence that synonymous variants outside the canonical splice sites in KCNQ1 can alter splicing and clinically impact phenotype. Through this mechanism, we identified that p.L353L can precipitate QT prolongation by itself and produce a clinically relevant interactive effect in conjunction with other LQTS variants.
Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial
Wahidi, Momen M. , Reddy, Chakravarthy, Yarmus, Lonny , Feller‐Kopman, David , Musani, Ali I., Shepherd, Ray W., Bechara, Rabih , Lamb, Carla, Shofer, Scott , Mahmood, Kamran , Michaud, Gaëtane , Puchalski, Jonathan , Rafeq, Samaan , Cattaneo, Stephen M., Mullon, John J., Leh, Steven, Mayse, Martin L., Thomas, Samantha , Peterson, Bercedis L., Light, Richard W., Mullon, John, Lee, Hans C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 6, 2017 | Volume: 195 | Issue: 8 | Pages: 1050-1057

10.1164/rccm.201607-1404oc | PMID 27898215 Get It

Abstract Rationale Patients with malignant pleural effusions have significant dyspnea and shortened life expectancy. Indwelling pleural catheters allow patients to drain pleural fluid at home and can lead to autopleurodesis. The optimal drainage frequency to achieve autopleurodesis and freedom from catheter has not been determined. Objectives To determine whether an aggressive daily drainage strategy is superior to the current standard every other day drainage of pleural fluid in achieving autopleurodesis. Methods Patients were randomized to either an aggressive drainage (daily drainage; n = 73) or standard drainage (every other day drainage; n = 76) of pleural fluid via a tunneled pleural catheter. Measurements and Main Results The primary outcome was the incidence of autopleurodesis following the placement of the indwelling pleural catheters. The rate of autopleurodesis, defined as complete or partial response based on symptomatic and radiographic changes, was greater in the aggressive drainage arm than the standard drainage arm (47% vs. 24%, respectively; P = 0.003). Median time to autopleurodesis was shorter in the aggressive arm (54 d; 95% confidence interval, 34–83) as compared with the standard arm (90 d; 95% confidence interval, 70 to nonestimable). Rate of adverse events, quality of life, and patient satisfaction were not significantly different between the two arms. Conclusions Among patients with malignant pleural effusion, daily drainage of pleural fluid via an indwelling pleural catheter led to a higher rate of autopleurodesis and faster time to liberty from catheter. Clinical trial registered with www.clinicaltrials.gov (NCT 00978939).
Preventing cardiovascular disease: Participant perspectives of the FAITH! Program
Dean, Patrick J., Lackore, Kandace A. , Jenkins, Sarah M. , Cohen, Consuelo, Johnson, Jacqueline , Ellis, Frances, Mangum, DC, Brewer, LaPrincess C. , Morrison, Eleshia J, Balls-Berry, Joyce E, Lackore, Kandace, Morrison, Eleshia J. P. , Balls‐Berry, Joyce E. , Hayes, Sharonne N. , Patten, Christi A.

Mayo Clinic

Journal of Health Psychology | March 2, 2017 | Volume: 24 | Issue: 12 | Pages: 1710-1723

10.1177/1359105317695878 | PMID 28810418 Get It

Striking cardiovascular health disparities exist among African-Americans in Minnesota compared to Whites; however, community-based interventions to address cardiovascular disease risk are lacking. This study explored participant perceptions of a culturally tailored, cardiovascular disease prevention program developed using a community-based participatory research process. Research participation perceptions, program benefits, and program satisfaction/acceptability were analyzed using a mixed-methods approach. Overall, acceptability was high. Findings highlight the favorable inclusion of African-Americans (research perception), knowledge gained about healthy lifestyle practices (benefits), and quality of the curriculum/speakers (satisfaction). Community-based participatory research may be useful in fostering the acceptability of behavior change interventions among marginalized African-American communities.
Pulmonologists’ and Primary Care Physicians’ Responses to an Adult Patient with Asthma Who Inquires about Using Electronic Cigarettes as a Smoking Cessation Tool
Nickels, Andrew S., Jenkins, Sarah M. , Tilburt, Jon C. , Hays, J. Taylor , Warner, David O.

Mayo Clinic

Annals of the American Thoracic Society | March 1, 2017 | Volume: 14 | Issue: 3 | Pages: 466-468

10.1513/annalsats.201610-828le | PMID 28248581 Get It